Bronchiolitis Obliterans Syndrome Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting bronchiolitis obliterans syndrome clinical trials across 4 countries. Studies span Phase 2, Phase 3. Top locations include Seattle, Washington, United States, Houston, Texas, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Bronchiolitis Obliterans Syndrome Trials at a Glance

6 actively recruiting trials for bronchiolitis obliterans syndrome are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Seattle, Houston, and Ann Arbor. Lead sponsors running bronchiolitis obliterans syndrome studies include Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, and Renovion, Inc..

Browse bronchiolitis obliterans syndrome trials by phase

Treatments under study

About Bronchiolitis Obliterans Syndrome Clinical Trials

Looking for clinical trials for Bronchiolitis Obliterans Syndrome? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bronchiolitis Obliterans Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bronchiolitis Obliterans Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Lung DiseasesBronchiolitis Obliterans SyndromeChronic Graft Versus Host Disease+1 more
Dana-Farber Cancer Institute45 enrolled6 locationsNCT05922761
Recruiting
Phase 2

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans SyndromeLung transplantationChronic lung allograft dysfunction
Steven Hays, MD30 enrolled1 locationNCT06018766
Recruiting

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

Hematopoietic and Lymphoid Cell NeoplasmBronchiolitis Obliterans Syndrome
Fred Hutchinson Cancer Center250 enrolled4 locationsNCT05250037
Recruiting

Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children

Bronchiolitis Obliterans Syndrome
The Hospital for Sick Children15 enrolled1 locationNCT04391335
Recruiting
Phase 3

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Pre-Bronchiolitis Obliterans Syndrome
Renovion, Inc.100 enrolled20 locationsNCT05654922
Recruiting
Phase 2

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation

Bronchiolitis Obliterans Syndrome (BOS)Bronchiolitis Obliterans (BO)
University Hospital, Basel, Switzerland20 enrolled3 locationsNCT03805477